Novartis, GlaxoSmithKline, and Lonza are among those participating in newly formed consortiums for developing and producing medical countermeasures.
Jun 20, 2012
By:
Patricia Van Arnum
Novartis, GlaxoSmithKline, and Lonza are among those participating in newly formed consortiums for developing and producing medical countermeasures.
|
The new guide outlines potential product life-cycle approaches to the change-management system of a pharmaceutical quality system
Jun 5, 2012
By:
Patricia Van Arnum
The new guide outlines potential product life-cycle approaches to the change-management system of a pharmaceutical quality system.
|
May 14, 2012
By:
Patricia Van Arnum
GlaxoSmithKline tenders offer of $13.00 per share in an unsolicited bid despite an earlier rejection by Human Genome Sciences.
|
May 7, 2012
By:
Patricia Van Arnum
The company receives FDA and EMA approval for expansion of fill and finish operations for alglucosidase alfa.
|
Apr 30, 2012
By:
Patricia Van Arnum
In a move designed to increase its international presence, Watson Pharmaceuticals has agreed to acquire Actavis for EUR 4.25 billion ($5.62 billion).
|
A new report by FDA details the strategies, programs, and other activities the agency is using to address the rise of imported pharmaceutical products and APIs.
Apr 23, 2012
By:
Patricia Van Arnum
A new report by FDA details the strategies, programs, and other activities the agency is using to address the rise of imported pharmaceutical products and APIs.
|
Apr 17, 2012
By:
Patricia Van Arnum
US spending on prescription drugs increased moderately in 2011 reflecting increased generic-drug incursion and lower spending on prescription drugs. Pfizer retained its number one position of the top company of US prescription drug sales, and the generic-drug company Teva Pharmaceutical moved into the top-five companies of US prescription drug sales.
|
Generic-drug incursion and reduced demand contribute to modest gains.
Apr 10, 2012
By:
Patricia Van Arnum
Generic-drug incursion and reduced demand contribute to modest gains.
|
Apr 10, 2012
By:
Patricia Van Arnum
On Mar. 29, 2012, the Generic Pharmaceutical Association (GPhA) reiterated its call for Congress to move forward with user-fee proposals for generic drugs and biosimilar products.
|
|
